Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
28 studies found for:    AMG479
Show Display Options
RSS Create an RSS feed from your search for:
AMG479
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors
Condition: Neoplasm Metastases
Intervention: Drug: RAD001 + AMG479
2 Completed QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors
Conditions: Advanced Malignancy;   Advanced Solid Tumors;   Cancer;   Solid Tumors;   Tumors
Intervention: Drug: AMG 479
3 Recruiting A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007
Condition: Advanced Solid Tumors, Non-small Cell Lung Cancer
Intervention: Drug: AMG 479, Everolimus, Panitumumab
4 Active, not recruiting AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Conditions: Neuroendocrine Tumor;   Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor
Intervention: Drug: AMG 479
5 Active, not recruiting A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
Conditions: PIK3CA Mutated Advanced Solid Tumors;   PIK3CA Amplified Advanced Solid Tumors
Interventions: Drug: BYL719;   Drug: AMG 479
6 Terminated A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Conditions: Metastatic Pancreatic Adenocarcinoma;   BRAF Mutated Melanoma
Interventions: Drug: MEK162;   Drug: AMG 479
7 Completed
Has Results
Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer
Condition: Ovarian Neoplasms
Intervention: Biological: AMG 479
8 Completed QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors
Conditions: Askin's Tumors;   Desmoplastic Small Round Cell Tumors;   Estraosseous Ewing's Tumor;   Ewing's Family Tumor;   Ewing's Sarcoma;   Primitive Neuroectodermal Tumors (PNETs);   Sarcoma
Intervention: Drug: AMG 479
9 Terminated QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
Conditions: Adenocarcinoma of the Pancreas;   Advanced Solid Tumors;   Cancer;   Cancer of Pancreas;   Cancer of the Pancreas;   Metastases;   Metastatic Cancer;   Metastatic Pancreatic Cancer;   Pancreas Cancer;   Pancreatic Cancer;   Bone Metastases;   Endocrine Cancer;   Oncology;   Oncology Patients;   Solid Tumors;   Advanced Malignancy
Interventions: Drug: AMG 479;   Drug: Placebo;   Drug: gemcitabine
10 Recruiting Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
Conditions: Rhabdomyosarcoma;   Rhabdomyosarcoma- Alveolar;   Rhabdomyosarcoma-Embryonal
Interventions: Drug: Dasatinib;   Drug: Ganitumab
11 Withdrawn Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab
Condition: Breast Cancer
Interventions: Drug: AMG 479;   Drug: Trastuzumab
12 Terminated QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
Conditions: Colorectal Cancer;   Locally Advanced;   Metastatic Cancer;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Sarcoma;   Solid Tumors
Interventions: Biological: AMG 479;   Biological: AMG 655
13 Active, not recruiting QUILT-3.030: Open Label Extension Study of Conatumumab and AMG 479
Conditions: Advanced Solid Tumors;   Carcinoid;   Colorectal Cancer;   Locally Advanced;   Lymphoma;   Metastatic Cancer;   Non-Small Cell Lung Cancer;   Sarcoma;   Solid Tumors
Interventions: Drug: FOLFOX6;   Biological: Conatumumab;   Biological: Ganitumab;   Biological: Bevacizumab
14 Terminated Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
Conditions: Adenocarcinoma of the Pancreas;   Locally Advanced;   Unresectable
Interventions: Drug: Gemcitabine;   Drug: AMG 479;   Drug: Placebo
15 Available Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma
Condition: Ewing Sarcoma
Intervention: Drug: Ganitumab
16 Terminated
Has Results
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: AMG 479;   Drug: AMG 479 Placebo
17 Terminated QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
Condition: Advanced Squamous Non-Small Cell Lung Cancer
Interventions: Biological: AMG 479;   Drug: Carboplatin;   Drug: Paclitaxel
18 Completed QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Metastatic Pancreatic Cancer;   Pancreatic Cancer
Interventions: Other: Placebo;   Drug: AMG 479;   Drug: AMG 655
19 Completed QUILT-2.013: A Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer
Conditions: Lung Cancer;   Small Cell Lung Cancer;   Solid Tumors;   Extensive-stage Small Cell Lung Cancer
Interventions: Drug: AMG 479;   Drug: Etoposide;   Drug: Placebo;   Drug: AMG 102;   Drug: Carboplatin;   Drug: Cisplatin
20 Completed
Has Results
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
Conditions: Colon Cancer;   Colorectal Cancer;   Gastrointestinal Cancer;   Metastatic Colorectal Cancer;   Rectal Cancer
Interventions: Drug: Panitumumab;   Drug: Ganitumab;   Drug: Rilotumumab;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-28) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.